Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

OptiBiotix to showcase industry-leading technology at top conference next month

The poster and verbal exposition will focus on OptiBiotix's ability to identify and develop targeted prebiotics
gut schematic
The gut is host to a whole ecosystem of bacteria which helps promote good health

OptiBiotix Health plc’s (LON:OPTI) work on the emerging field of the human microbiome will be recognised at a leading industry conference next month.

For the company is to present an abstract at ProBiota 2018, attended by the movers and shakers of the industry.

READ: Optibiotix Health eyes up future projects

The poster and verbal exposition will focus on OptiBiotix's ability to identify and develop targeted prebiotics which can enhance the growth rate and health benefits of specific microbial species. In doing so they aid the efficacy of probiotic products.

Deeper dive

To understand what this means it is worth going back to first principles. As mentioned, the company’s focus is the human microbiome, an ecosystem of bacteria and yeasts that reside in the gut and on the skin.

It is thought changes to the human flora can have an impact on health, hence the proliferation of functional foods such as yoghurts filled with probiotic, or good bacteria.

OptiBiotix’s focus is mainly on the gut with advances designed to tackle obesity, cholesterol and diabetes although the company does have a separately-quoted business developing skincare products.

What it is showcasing at the ProBiota conference is a prebiotic which helps promote the growth of the health-giving micro-organisms such as Lactobacillus rhamnosus GG, or LGG for short.

This new product concept utilises OptiBiotix's synbiotics technology and has the potential to enhance probiotic health benefits and provide a product that is different to the current me-too offerings.

Designer prebiotics

“The ability to create designer prebiotics which can selectively modulate the growth of an individual species and be used in combination to improve the efficacy of existing probiotics, or by itself to modify an individual's microbiome to improve health, is a hugely exciting development in global microbiome research and product development,” said OptiBiotix chief executive Stephen O’Hara.

“We believe we are fast approaching a future where microbiome products will make a significant contribution to the prevention, management and treatment of disease.

“The ability to create designer ingredients which can precision engineer the microbiome to improve health places OptiBiotix at the forefront of this global health trend."

ProBiota 2018 takes place in Barcelona February 7-9.

View full OPTI profile View Profile

OptiBiotix Health plc Timeline

Related Articles

November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
June 06 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
Workers at CERN
August 02 2018
Private banks and healthcare groups took part in the share placing

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use